GlassScriptPhysician profile
Francisco Pons
NPI 1508849027
$5,801.33
in general payments reported to CMS, 2019-2025
22 companies · $634 in 2025
The $634 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,208 · 2020: $599 · 2021: $1,214 · 2022: $655 · 2023: $589 · 2024: $902 · 2025: $634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,045 · Education: $79.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,045.43 |
| Education | $79.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $2,057.61 | 2019-2025 | Veltassa |
| Astrazeneca Pharmaceuticals LP | $852.24 | 2019-2025 | Farxiga, Lokelma |
| Opko Pharmaceuticals, LLC | $545.37 | 2019-2025 | Rayaldee |
| Akebia Therapeutics INC | $284.34 | 2019-2024 | Vafseo |
| Fresenius USA Marketing, INC. | $276.49 | 2019-2025 | Velphoro, Velphoro |
| Amgen INC. | $263.86 | 2019-2024 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $228.11 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $210.02 | 2020-2025 | Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $189.37 | 2021-2025 | |
| Horizon Therapeutics Plc | $143.57 | 2021-2022 | |
| Ardelyx, INC. | $120.66 | 2024-2025 | Ibsrela |
| Calliditas Therapeutics US INC. | $111.10 | 2022-2025 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $91.34 | 2021-2023 | Lupkynis |
| Mallinckrodt Enterprises LLC | $81.27 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.18 | 2024 | Jardiance |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $57.19 | 2019 | |
| Kyowa Kirin, INC. | $52.54 | 2023-2024 | Crysvita |
| Glaxosmithkline, LLC. | $52.20 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $40.50 | 2021-2023 | |
| Travere Therapeutics, INC. | $37.41 | 2019-2022 | |
| Novo Nordisk INC | $13.71 | 2025 | Ozempic, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $13.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Francisco Pons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.